Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tempest Therapeutics (Nasdaq: TPST), a clinical-stage biotechnology company focused on developing targeted and immune-mediated cancer therapeutics, has announced the granting of stock options to two employees. The Compensation Committee of the company's Board of Directors approved nonqualified stock options for the purchase of 79,500 shares of common stock under Tempest's 2023 Inducement Plan.
The stock options have a four-year vesting period, with 25% vesting on the first anniversary of each employee's start date, followed by 1/48th of the total shares vesting monthly thereafter. The vesting is subject to continued employment on each vesting date. This announcement is made in accordance with Nasdaq Listing Rule 5635(c)(4), which pertains to inducement grants for new employees.
Tempest Therapeutics (Nasdaq: TPST), una società biotecnologica in fase clinica focalizzata sullo sviluppo di terapie oncologiche mirate e mediate dal sistema immunitario, ha annunciato l'assegnazione di opzioni su azioni a due dipendenti. Il Comitato per la Remunerazione del Consiglio di Amministrazione dell'azienda ha approvato opzioni su azioni non qualificate per l'acquisto di 79.500 azioni ordinarie nell'ambito del Piano di Induzione 2023 di Tempest.
Le opzioni azionarie prevedono un periodo di maturazione di quattro anni, con il 25% che matura al primo anniversario della data di assunzione di ciascun dipendente, seguito da un mese di maturazione per 1/48 delle azioni totali. La maturazione è soggetta alla continuazione dell'impiego in ciascuna data di maturazione. Questo annuncio è fatto in conformità con la Regola di Insediamento 5635(c)(4) di Nasdaq, che riguarda le concessioni di induzione per nuovi dipendenti.
Tempest Therapeutics (Nasdaq: TPST), una empresa biotecnológica en fase clínica centrada en el desarrollo de terapias contra el cáncer dirigidas e inmunomediadas, ha anunciado la concesión de opciones sobre acciones a dos empleados. El Comité de Compensación de la Junta Directiva de la compañía aprobó opciones sobre acciones no calificadas para la compra de 79,500 acciones ordinarias bajo el Plan de Inducción 2023 de Tempest.
Las opciones sobre acciones tienen un período de consolidación de cuatro años, con un 25% consolidándose en el primer aniversario de la fecha de inicio de cada empleado, seguido de 1/48 del total de acciones consolidándose mensualmente a partir de entonces. La consolidación está sujeta a la continuación del empleo en cada fecha de consolidación. Este anuncio se realiza de acuerdo con la Regla de Listado 5635(c)(4) de Nasdaq, que se refiere a las concesiones de indución para nuevos empleados.
템페스트 테라퓨틱스(나스닥: TPST)는 임상 단계 생명공학 회사로서 표적 및 면역 매개 암 치료제 개발에 집중하고 있으며, 두 직원에게 스톡 옵션을 부여했다고 발표했습니다. 회사의 자문위원회는 템페스트의 2023 유도 계획에 따라 79,500주의 보통주 구매를 위한 비자격 스톡 옵션을 승인했습니다.
스톡 옵션은 4년의 베스팅 기간을 가지며, 각 직원의 시작일 첫 번째 기념일에 25%가 베스팅되고, 이후 매달 총 주식의 1/48이 베스팅됩니다. 베스팅은 각 베스팅 날짜에 계속 고용 상태를 유지해야 합니다. 이 발표는 새로운 직원에게 유도 보상에 관한 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Tempest Therapeutics (Nasdaq: TPST), une entreprise de biotechnologie en phase clinique axée sur le développement de thérapies anticancéreuses ciblées et immunomédiées, a annoncé l'octroi de stock options à deux employés. Le Comité de rémunération du Conseil d'administration de l'entreprise a approuvé des options sur actions non qualifiées pour l'achat de 79 500 actions ordinaires dans le cadre du Plan d'incitation 2023 de Tempest.
Les options d'achat d'actions ont une période d'acquisition de quatre ans, avec 25 % qui acquiert un droit lors du premier anniversaire de la date de début de chaque employé, suivi par 1/48 des actions totales acquérant un droit mensuellement par la suite. L'acquisition des droits est soumise à la continuité de l'emploi à chaque date d'acquisition. Cette annonce est faite conformément à la Règle d'inscription 5635(c)(4) de Nasdaq, qui concerne les octrois d'incitation pour les nouveaux employés.
Tempest Therapeutics (Nasdaq: TPST), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von gezielten und immunvermittelten Krebstherapeutika konzentriert, hat die Vergabe von Aktienoptionen an zwei Mitarbeiter bekannt gegeben. Der Vergütungsausschuss des Vorstands des Unternehmens genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 79.500 Aktien des Stammkapitals im Rahmen des Induktionsplans 2023 von Tempest.
Die Aktienoptionen haben eine vierjährige Vestingperiode, wobei 25% am ersten Jahrestag des Eintritts eines jeden Mitarbeiters vested, gefolgt von monatlichem Vesting von 1/48 der gesamten Aktien. Das Vesting ist an die Fortsetzung der Anstellung an jedem Vesting-Datum gebunden. Diese Ankündigung erfolgt gemäß der Nasdaq Listing Regel 5635(c)(4), die sich auf Induktionsvergaben für neue Mitarbeiter bezieht.
- Tempest Therapeutics is attracting and retaining talent through stock option grants
- The company has a structured 2023 Inducement Plan in place for employee compensation
- None.
BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 79,500 shares of its common stock under the Company’s 2023 Inducement Plan.
The stock options will vest over a four-year period, with
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at www.tempesttx.com.
Investor & Media Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
1 If approved by the FDA
FAQ
How many shares of common stock were granted as stock options by Tempest Therapeutics (TPST)?
What is the vesting schedule for the stock options granted by Tempest Therapeutics (TPST)?
Under which plan were the stock options granted by Tempest Therapeutics (TPST)?
What Nasdaq rule is mentioned in Tempest Therapeutics' (TPST) announcement of inducement grants?
